October 23, 2007 – After 12 months of the SPIRIT III trial, there were significantly fewer major adverse cardiac ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
OCTOBER 23, 2007 – Abbott’s fully bioabsorbable drug eluting stent platform for the treatment of coronary artery disease ...
October 22, 2007
October 22, 2007 - Implantation of the CYPHER Sirolimus-eluting Coronary Stent by Cordis Corp. used to treat completely ...
October 21, 2007October 22, 2007 – Stent thrombosis rates through one year were low for both the TAXUS Express2 Paclitaxel-Eluting ...
October 21, 2007October 18, 2007 – XTENT Inc. announced that two-year data from the CUSTOM I trial and 1-year data from the CUSTOM II ...
October 17, 2007October 18, 2007 - Cordis Corp. will present clinical data backing the CYPHER Sirolimus-eluting coronary stent at the ...
October 17, 2007October 18, 2007 - Abbott announced that trial results for ABSORB, the world’s first clinical trial evaluating the ...
October 17, 2007
Feature | Cristen C. Bolan
Ever since the BASKET-LATE study came out suggesting an increase in the rate of death and myocardial infarction in ...
October 17, 2007October 17, 2007 - Compared to bare metal stents, in patients with acute myocardial infarction, sirolimus-eluting stent ...
October 16, 2007October 17, 2007 - Boston Scientific Corp. will be presenting safety and efficacy data on its TAXUS Express2 and TAXUS ...
October 16, 2007October 17, 2007 — The first trial to test whether medicated, drug-eluting (dispensing), stents can benefit patients who ...
October 16, 2007October 16, 2007 - MIV Therapeutics Inc., a developer of coatings and drug delivery systems for cardiovascular stents ...
October 15, 2007October 10, 2007 - Medtronic Inc. announced that an FDA advisory committee has recommended the Endeavor drug-eluting ...
October 10, 2007October 9, 2007 - Medtronic Inc. will provide a synopsis of clinical data on the Endeavor Drug Eluting Coronary Stent to ...
October 08, 2007October 8, 2007 - Drug-eluting stents were found to be most effective in reducing the need for repeat angioplasty ...
October 07, 2007© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now